– Enhances competitiveness with 30% reduction in cooling energy consumption

– Supports high-density, high-efficiency, and eco-friendly data center construction through 4D differentiation strategy

SINGAPORE–(BUSINESS WIRE)– KAYTUS, a leading provider of end-to-end AI and liquid cooling solutions, has introduced its One-Stop End-to-End Liquid-Cooled Data Center Solution in response to the surging demand for AI adoption and energy efficiency.

The solution is designed with the concepts of modularization, prefabrication, and safety, supporting up to 15 kW per node and 130 kW per cabinet, with a PUE below 1.1. It provides an end-to-end liquid cooling solution covering design, development, deployment, and operation, addressing the complexity and high entry barriers of large-scale liquid-cooled deployment while supporting eco-friendly data center operations aligned with the government’s carbon neutrality initiatives.

Rapid Growth of Domestic AI Market Highlights Urgent Need for Energy Efficiency

The AI industry is rapidly expanding, driven by the launch of the Presidential National AI Strategy Committee in September 2025. The government aims to position Korea among the world’s top three AI powers through large-scale infrastructure investments, including the National AI Computing Center project, accelerating nationwide digital transformation. Driven by policy incentives, enterprise demand for building AIDCs has surged. At the same time, with the enforcement of the Framework Act on Carbon Neutrality and Green Growth and the RE100 policy, it has become imperative to explore how to meet the growing demand for high AI computing power while leveraging next-generation data center technologies to achieve sustainable development.

Multiple challenges with a huge and highly systematic liquid cooled establishment

Compared with traditional air cooling, liquid cooling has become the de facto standard for AI data centers thanks to its superior heat exchange efficiency and energy performance. However, from both a technical and engineering perspective, deploying a liquid-cooled data center presents significant challenges. To enable the rapid deployment of ultra-high-density system, the liquid cooling system faces a range of hurdles across planning, deployment, tuning, and ongoing operations. Designing involves interdisciplinary coordination across power distribution, HVAC path planning, structural load considerations, and airflow management. Deploying involves coordinating multiple contractors and managing concurrent construction activities. Tuning liquid-cooled systems requires cross-disciplinary collaboration. Operation requires careful management of coolant control, leak prevention, and fault diagnostics. To address those challenges, Users need partners with extensive technical expertise and deployment experience across these domains.

Customized “4D Integrated Solution” Simplifies Deployment Complexity

KAYTUS’s liquid-cooled DC solution for AI applies its 4D differentiation strategy—Design, Develop, Deploy, and Dynamic Optimization—to address the key challenges enterprises face when building liquid-cooled data centers.

Design: KAYTUS is one of the first in the data center industry to provide Building Information Modeling (BIM) design blueprints, enabling customers to visually preview the actual construction outcome in advance. The company offers the consulting service of datacenter early construction planning such as the primary loop analysis, and the complete secondary loop design, covering CDU, liquid cooling ring network, coolant, HVAC pathways and more.

Develop: KAYTUS offers a full-stack product portfolio, encompassing servers, storage, networking, CDUs (Coolant Distribution Units), cooling loops, and intelligent operation and management platforms such as KSManage and MotusAI. By integrating IT equipment with cooling infrastructure, KAYTUS maximizes system compatibility and reliability.

Deploy: By applying modular and prefabricated designs, KAYTUS pre-integrates and tests key components, pipelines, and equipment at the factory, improving delivery efficiency by more than 50%. With around 200 MW of project deployment experience across major regions, KAYTUS has proven its large-scale implementation capability.

Dynamic Optimization: KAYTUS provides benchmarking, performance validation, and system-tuning services for AI and HPC (High-Performance Computing) workloads. Comprehensive network and performance stress testing—from individual nodes to entire racks and cross-rack systems—ensures optimal computing performance and stable, reliable operations.

Technological Innovation for High-Density and Sustainable Infrastructure

The KAYTUS liquid-cooled AIDC solution supports up to 15 kW per node and 130 kW per cabinet, achieving a PUE below 1.1.

In particular, KAYTUS’s self-developed megawatt-class CDU delivers a heat exchange capacity of up to 1,200 kW with a primary inlet water temperatures of 36°C and a secondary supply liquid temperature of 40°C, ensuring stable performance even in Korea’s hot summer conditions. The solution also features a leak detection system and a dual-valve safety design, which automatically isolates only the affected cabinet in the event of a leak to minimize system impact.

The coolant fully complies with EU RoHS 2.0 and REACH regulations, with zero detection of 233 SVHC (Substances of Very High Concern), ensuring environmental safety and long-term reliability.

Prefabricated Container Solution for Rapid Deployment

To meet enterprises’ growing need for fast AI service launches, KAYTUS offers a prefabricated container solution that dramatically shortens data center construction time by 80%. A traditional data center with a scale of 500 racks takes about 18 months to build, while the container solution—where around 90% of assembly and testing is completed in the factory—can shorten the timeline to just 4 months.

In addition, Container solution integrates green energy-saving technologies such as liquid cooling, photovoltaic, energy storage, and waste heat recovery to reduce PUE below 1.1.

The solution also features on-demand customization. It has eight functional container types that can be flexibly combined to suit scenario of AI, general-purpose, and edge applications. It also supports horizontal and vertical expansion—up to five layers—enabling rapid and scalable deployment to meet urgent AI infrastructure needs.

Proven Global Success Cases

KAYTUS has extensive experience in building large-scale liquid-cooled data centers with over 1,000 cabinets across major regions. A notable example is a project for a leading financial firm in Europe, where KAYTUS provided an end-to-end turnkey service covering the design, construction, and operation of 96 rack-scale liquid-cooled systems. By implementing an innovative ring network piping design, 100 kW independent liquid-cooling cabinets, and an intelligent leak detection system, the company ensured 24/7 uninterrupted operation while significantly reducing operational risks.

About KAYTUS

KAYTUS is a leading provider of end-to-end AI and liquid cooling solutions, delivering a diverse range of innovative, open, and eco-friendly products for cloud, AI, edge computing, and other emerging applications. With a customer-centric approach, KAYTUS is agile and responsive to user needs through its adaptable business model. Discover more at KAYTUS.com and follow us on LinkedIn and X

View source version on businesswire.com: https://www.businesswire.com/news/home/20260113195145/en/

Contacts

Media Contacts
media@kaytus.com

New agreement for uninterrupted UHF connectivity for Australian Defence Force through 2033, With Options Extending to 2041

LUXEMBOURG–(BUSINESS WIRE)– Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/

Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit

Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the cornerstone of Australia’s secure military communications since IS-22’s launch in 2012. SES will build a dedicated ground segment, including a purpose-built antenna facility on Australian soil, solidifying the infrastructure needed for seamless operations now and into the future.

“This agreement ensures critical communications capability for the ADF and its strategic partners across the Indo-Pacific,” said Philippe Glaesner, SVP of SES Global Government. “At a time when secure, sovereign communications are more vital than ever, it provides operational certainty and supports Australia’s long-term resilience and leadership in defense. We are proud to serve as both a technological partner and strategic enabler for the ADF.”

The IS-22 satellite’s UHF payload has been virtually irreplaceable for the Australian Defence Force, supporting both national missions and joint operations with key allies, most notably the United States. With no other comparable UHF capacity immediately available in the Indo-Pacific, the continuation of service via IS-22 positions Australia to maintain a critical communications advantage, while supporting multinational defense collaboration.

The current industry context has seen a sharp increase in demand for secure military satellite communications worldwide, particularly in UHF, where supply is extremely limited. By securing access to the IS-22’s capabilities for years to come, the ADF will maintain not only continuity but a strategic edge in command and control, secure mobility, and coalition interoperability.

Follow us on:

Twitter | Facebook | YouTube | LinkedIn | Instagram

Read our Blogs >

Visit the Media Gallery >

About SES

At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry leadership—backed by a track record of bringing innovation “firsts” to market. As a trusted partner to customers and the global space ecosystem, SES is driving impact that goes far beyond coverage. The company is headquartered in Luxembourg and listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com

Forward-looking Statements

This press release contains certain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “will” and “ensures”.

Forward-looking statements are not assurances of future performance and are subject to inherent uncertainties and risks that are difficult to predict. Factors that might cause such a difference include those discussed in our filings with the US Securities and Exchange Commission, including our Form F-4, such as disruptions to information systems, satellite control and operations networks and other technology as a result of unauthorized access, misappropriation of data or other malfeasance. The forward-looking statements included in this press release are made only as of the date hereof and we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260112137182/en/

Contacts

Steven Lott

Communications

Tel. +352 710 725 500

SES.Press@ses.com

Not intended for Canada-, UK- or US-based media

DARMSTADT, Germany–(BUSINESS WIRE)– Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib.

“With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain and stiffness in the global Phase 3 MANEUVER study, we are confident in the important role pimicotinib can play for TGCT patients in the U.S. and worldwide.”

The application is based on primary and longer-term results from the global Phase 3 MANEUVER study. In this trial, once-daily pimicotinib demonstrated a statistically significant improvement in the primary endpoint of objective response rate (ORR) assessed by blinded independent review committee (BIRC) by RECIST v1.1 compared with placebo at week 25. The study also demonstrated statistically significant and clinically meaningful improvements in all secondary endpoints related to key patient-reported outcomes in TGCT, including improvements in active range of motion and physical function and reductions in stiffness and pain. These findings were presented at the 2025 ASCO Annual Meeting. Longer-term results with median follow-up of 14.3 months presented at ESMO Congress 2025 showed ORR continued to increase over time among patients treated with pimicotinib from the beginning of the study.

TGCT is a rare, locally aggressive tumor occurring in or around the joint leading to progressive swelling, stiffness and reduced mobility of the affected joint, significantly impacting daily activities and quality of life in what is typically an otherwise healthy population. If left untreated or in recurrent cases, TGCT may result in irreversible damage to the bone, joint and surrounding tissues. A significant need remains for highly effective and well-tolerated treatments beyond surgery that can not only shrink tumors but also alleviate pain and restore function.

In December 2025, pimicotinib was approved by the China National Medical Products Administration (NMPA) for the treatment of adult patients with symptomatic TGCT for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Additional applications are under review by regulatory bodies in other markets.

About MANEUVER

The pivotal global Phase 3 MANEUVER study is a three-part, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of pimicotinib in patients with TGCT who require systemic therapy and have not received prior anti-CSF-1/CSF-1R therapy. The study is being conducted by Abbisko Therapeutics in China (n=45), Europe (n=28), and the US and Canada (n=21).

In the double-blind Part 1, 94 patients were randomized 2:1 to receive either 50 mg QD of pimicotinib (n=63) or placebo (n=31) for 24 weeks. The primary endpoint was objective response rate (ORR) at week 25, as measured by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by blinded independent central review (BICR) in the intent-to-treat (ITT) population. Secondary endpoints include ORR per tumor volume score (TVS), relative range of motion, stiffness by Numeric Rating Scale (NRS), pain by Brief Pain Inventory (BPI), and physical function measured by Patient-Reported Outcomes Measurement Information System (PROMIS-PF).

After the double-blind Part 1, eligible patients could continue to the open-label Part 2 for up to 24 weeks of further treatment. Patients who completed Part 2 could then enter the open-label extension phase (Part 3) for extended treatment and safety follow-up.

About pimicotinib (ABSK021)

Pimicotinib, developed by Abbisko Therapeutics, is a novel, orally administered, highly selective and potent small-molecule inhibitor of CSF-1R. Pimicotinib is the first systemic treatment for TGCT to be approved in China. It has been granted breakthrough therapy designation (BTD) for the treatment of inoperable TGCT by the U.S. Food and Drug Administration (FDA), and priority medicine (PRIME) designation from the European Medicines Agency (EMA). Merck KGaA, Darmstadt, Germany, holds worldwide commercialization rights for pimicotinib.

About Merck

Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2024, Merck generated sales of € 21.2 billion in 65 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.

All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260108489017/en/

Contacts

Media Relations
noelle.piscitelli@emdserono.com
Phone: +1 (781) 427-4351

Investor Relations
investor.relations@merckgroup.com
Phone: +49 6151 72-3321

SINGAPORE–(BUSINESS WIRE)– Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support.

UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP).

“For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP/GM, Merchant Shopping, Google.

Powered by UCP, AI surfaces — like the Gemini app or AI Mode in Google Search — are evolving. They will soon enable users to complete purchases natively within the chat interface. When a user expresses shopping intent, the AI intuitively understands their needs and presents a curated selection of products. With a single tap on “Pay with GPay,” users can review their order and finalise payment without ever leaving the conversation. Shopping is now faster, simpler, and more frictionless than ever.

“Ant International is thrilled to deepen our collaboration with Google and support the Agentic Commerce ecosystem. By leveraging our leading payment capabilities, Ant International is creating unique agentic commerce solutions for merchants by delivering merchant friendly, seamless user experience and end-to-end trust, ultimately driving business growth,” says Jiang-Ming Yang, Chief Innovation Officer, Ant International.

Ant International’s agentic commerce solutions aim to provide merchants with three critical capabilities to scale in AI-enabled commerce:

1. Control over algorithmic engagement

In agentic commerce, engagement shifts from human browsing to AI-mediated decision-making. Ant International enables merchants to remain in control, allowing them to define how their brand, offers, loyalty programs, and memberships are represented and executed by AI agents. Brands can now automate engagement while guaranteeing a customer experience that consistently reflects their brand identity and service excellence.

2. A seamless, agent-native experience

Ant International leverages its deep expertise in alternative payment methods (APMs) and its close ties with leading digital wallets to develop APM-based agentic payment solutions. With the support of Antom EasySafePay, users can remain entirely within their AI experience throughout the shopping and checkout journey.

3. Trust across the agentic shopping journey

Trust is foundational to agentic commerce, where users delegate purchasing authority to AI. Ant International ensures that user intent is verifiable, transactions are traceable, and accountability is clear for every participant across the payment lifecycle. EasySafePay leverages Multi-Party Computation (MPC)-based AI risk management and mobile device security systems to identify and block fraudulent transactions, while also providing a money-back guarantee for payment partners in cases of account takeover fraud.

Ant International focuses on providing payment services to merchants, fintechs and banks. Its global payments services, global account, as well as AI and other fintech solutions now cover 200+ markets, connecting 1.8 billion user accounts and 150 million merchants, especially in the emerging markets of Asia Pacific.

To ensure secure, interoperable, and automated transactions among intelligent agents, Ant International is investing actively to co-develop new agentic protocols with industry partners. Other ongoing parentships include the Agent Payments Protocol (AP2) by Google and programs to pilot card-based transaction capabilities for AI agents with global card networks.

About Ant International

With headquarters in Singapore and main operations across Asia, Europe, the Middle East and Latin America, Ant International is a leading global digital payment, digitisation and financial technology provider. Through collaboration across the private and public sectors, our unified techfin platform supports financial institutions and merchants of all sizes to achieve inclusive growth through a comprehensive range of cutting-edge digital payment and financial services solutions. To learn more, please visit https://www.ant-intl.com/

View source version on businesswire.com: https://www.businesswire.com/news/home/20260111092027/en/

Contacts

For media enquiries, please contact
Ant International Global Communications

pr@ant-intl.com

• Anthropic’s safety-first AI meets Allianz’s dedication to customer centricity, stakeholder trust, and regulatory excellence
• Three focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance

MUNICH & SAN FRANCISCO–(BUSINESS WIRE)– Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy.

“With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.

“Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those who depend on it,” said Dario Amodei, CEO and Co-Founder of Anthropic.

Three Projects Driving Responsible AI Innovation

The partnership will concentrate on three key areas of collaboration, with initial projects already in progress:

1. Empowering People and Reimagining Code with AI

With foundational models built to address the unique insurance requirements, Anthropic is helping Allianz transform its operations with AI. Anthropic’s “Claude” models will become part of Allianz’s internal AI platform that is free to use for everyone within Allianz. “Claude Code” is already redefining software development for thousands of Allianz developers globally. Model Context Protocols (MCPs) will help employees to securely connect and integrate various data sources across different applications or services.

2. Agentic AI Automation for Speed and Customer Excellence

Allianz and Anthropic are developing custom AI agents capable of orchestrating multi-step workflows and automating labor-intensive processes at scale – from intake documentation to claims processing in areas such as motor and health insurance. The result: fewer manual steps, faster first payments, and a better experience for claimants when it matters most. This experience includes Allianz’s human-in-the-loop principle: Especially in sensitive or very complex cases, Allianz employees take over and make sure claims are handled empathically.

3. Driving Transparency and Compliance with AI

The partnership is co-developing AI systems that, inter alia, log every decision, rationale, and data source to address insurance-specific risks and regulatory requirements, ensuring that all AI-driven actions are fully traceable and compliant.

A Partnership Built on Shared Values

This partnership is grounded in shared principles. Anthropic’s focus on AI safety – reflected in its Responsible Scaling Policy and constitutional AI principles – complements Allianz’s long-standing dedication to customer centricity, stakeholder trust and regulatory excellence. Together, they will build AI that supports human decision-making, safeguards customers, and minimizes risk.

Allianz’s Track Record of Improving Customer Experiences with AI

Allianz combines cutting-edge technology with human oversight to deliver smarter services while prioritizing transparency and data security. An Allianz Partners voice assistant, for example, provides roadside assistance in multiple languages prioritizing urgent calls. Allianz Australia has launched an AI solution to automate food spoilage claims due to power outages, which significantly reduces turnaround time; Allianz Versicherungs-AG can pay pet insurance invoices within four hours thanks to AI. Overall, Allianz aims to use AI to bring the customer experience to a new level at every touchpoint. Click here to learn more.

Upskilling Employees

To drive the successful application of AI at Allianz, the company is investing in upskilling its people, as AI skills are essential for every member of the Allianz workforce. With a variety of global learning programs, Allianz prepares all employees for the challenges and opportunities ahead. Click here to learn more.

About Allianz

The Allianz Group is one of the world’s leading insurers and asset managers serving private and corporate customers in nearly 70 countries. Allianz customers benefit from a broad range of personal and corporate insurance services, ranging from property, life and health insurance to assistance services to credit insurance and global business insurance. Allianz is one of the world’s largest investors, managing around 761 billion euros* on behalf of its insurance customers. Furthermore, our asset managers PIMCO and Allianz Global Investors manage about 1.9 trillion euros* of third-party assets. Thanks to our systematic integration of ecological and social criteria in our business processes and investment decisions, we are among the leaders in the insurance industry in the Dow Jones Sustainability Index. In 2024, over 156,000 employees achieved total business volume of 179.8 billion euros and an operating profit of 16.0 billion euros for the Group.

* As of September 30, 2025.

Mandatory corporate information: Corporate disclosures

These assessments are, as always, subject to the disclaimer provided below.

Cautionary note regarding forward-looking statements

This document includes forward-looking statements, such as prospects or expectations, that are based on management’s current views and assumptions and subject to known and unknown risks and uncertainties. Actual results, performance figures, or events may differ significantly from those expressed or implied in such forward-looking statements.

Deviations may arise due to changes in factors including, but not limited to, the following: (i) the general economic and competitive situation in the Allianz’s core business and core markets, (ii) the performance of financial markets (in particular market volatility, liquidity, and credit events), (iii) adverse publicity, regulatory actions or litigation with respect to the Allianz Group, other well-known companies and the financial services industry generally, (iv) the frequency and severity of insured loss events, including those resulting from natural catastrophes, and the development of loss expenses, (v) mortality and morbidity levels and trends, (vi) persistency levels, (vii) the extent of credit defaults, (viii) interest rate levels, (ix) currency exchange rates, most notably the EUR/USD exchange rate, (x) changes in laws and regulations, including tax regulations, (xi) the impact of acquisitions including related integration issues and reorganization measures, and (xii) the general competitive conditions that, in each individual case, apply at a local, regional, national, and/or global level. Many of these changes can be exacerbated by terrorist activities.

No duty to update

Allianz assumes no obligation to update any information or forward-looking statement contained herein, save for any information we are required to disclose by law.

Privacy Note

Allianz SE is committed to protecting your personal data. Find out more in our privacy statement.

About Anthropic

Anthropic is an AI research and development company that creates reliable, interpretable, and steerable AI systems. Anthropic’s flagship product is Claude, a large language model trusted by millions of users worldwide. Learn more about Anthropic and Claude at anthropic.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260109004903/en/

Contacts

For further information please contact at Allianz:
Lauren Day

Phone: +49 89 3800 3345

E-Mail: lauren.day@allianz.com

Florian Amberg

Phone: +49 89 3800 15924

E-Mail: florian.amberg@allianz.com

Heidi Polke

Phone: +49 89 3800 90777

E-Mail: heidi.polke@allianz.com

Susanne Seemann

Phone: +49 89 3800 18170

E-Mail: susanne.seemann@allianz.com

For further information please contact at Anthropic:
Lewis Maconachy

Phone: +44 7445534728

E-Mail: lewis@anthropic.com

HANGZHOU, China–(BUSINESS WIRE)– A recent survey by Life Times, a well-known Chinese public health media outlet, shows that AI doctor services are broadly supported by doctors in China. Among 500 physicians from the country’s top-tier (tertiary) hospitals, more than 70% said they would recommend AI doctor services to patients for everyday health questions and routine health management.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108456917/en/

Ant Group’s AI-native health app AQ is designed to address common, everyday health concerns and support healthy habit formation.

Ant Group’s AQ was the most frequently recommended platform in the survey. The latest figures show that, as of January 2026, the app had accumulated 30 million monthly active users and answers over 10 million health-related questions daily, making it China’s leading AI-native health app.

AQ—known in Chinese as Ant A-Fu—is an AI-native health app launched by Ant Group in June 2025. Designed to address common, everyday health concerns and support healthy habit formation, AQ focuses on users’ routine health needs that don’t yet require a hospital visit. Check out this video to see how it works:

https://www.youtube.com/shorts/mZwB0djjcDo

The platform connects users to digital services from 5,000 hospitals, online consultations with 300,000 doctors nationwide, and assistance from over 500 AI Doctor Agents co-developed with top physicians and key hospital departments across China.

Although AQ does not provide medical diagnoses or replace licensed physicians, doctors surveyed said they value AI doctor services for their ability to handle large volumes of patient questions without time or location constraints. Respondents noted that AI systems draw on extensive domain knowledge, can handle large volumes of consultations, respond patiently, and help ease patient anxiety—particularly for routine or repetitive inquiries.

AQ has also partnered with leading physicians across China to launch their AI Doctor Agents on the platform. These agents are trained on each doctor’s clinical experience and provide free responses to users’ health questions. Collectively, the AI Doctor Agents have answered more than 27 million health inquiries in 2025.

One example is Mao Hongjing, Deputy Director of Hangzhou Seventh People’s Hospital and a nationally recognized sleep specialist. Before adopting AI, Mao could treat roughly 10,000 patients per year in person. In contrast, his AI Doctor Agent on AQ has responded to inquiries from 3.68 million users within a single year.

Beyond patient-facing use, the survey found that over 60% of doctors already use AI doctor services to support their work, while over 90% are optimistic about the future development of AI doctors.

The use of AI in healthcare is taking place against the backdrop of China’s demographic shift. According to the National Bureau of Statistics, by the end of 2024, China had 310 million people aged 60 or above, accounting for 22% of the population. Projections from the World Health Organization indicate that this share could rise to nearly 28% by 2040.

An aging population is expected to drive greater demand for healthcare services. According to Grand View Research, China’s AI in healthcare market is projected to grow from US$ 1.6 billion in 2023 to nearly US$ 19 billion by 2030.

To meet this rising demand, hospitals and physicians across China are partnering with technology companies to explore how AI can improve healthcare efficiency while expanding access to quality medical services for a broader population.

About Ant Group

Ant Group is a global digital technology provider and the operator of Alipay, a leading internet services platform in China, connecting over one billion users to more than 10,000 types of consumer services from partners. Through innovative products and solutions powered by AI, blockchain and other technologies, Ant Group supports partners across industries to thrive through digital transformation in an ecosystem for inclusive and sustainable development. For more information, visit www.antgroup.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260108456917/en/

Contacts

Media Inquiries
Yinan Duan

duanyinan.dyn@antgroup.com

Another Year of “Good Boring” through Specialization

Closed $25+ Billion in Financing Commitments in 2025

Raised a Firm Record $20.5 Billion of New Investment Capital

Launched GP-Led Secondaries Strategy

NEW YORK–(BUSINESS WIRE)– Golub Capital delivered another year of “good boring,” consistent results for its stakeholders in 2025, aided by its commitment to specialization.

“We have long believed that specialization is a key source of competitive advantage for Golub Capital,” said David Golub, President of the Firm. “The past year validated this. Our deep relationships, scale and expertise enabled us to continue delivering strong results for investors, sponsors, portfolio companies and our team despite a muted M&A environment and high levels of credit stress across the private equity ecosystem. We are grateful for our clients’ trust and remain committed to building long-term, win-win partnerships that endure through market cycles.”

2025 Highlights, based on preliminary results:¹

Delivering strong credit performance, record fundraising and continued leadership in sponsor finance

• Closed $25+ billion in financing commitments in 2025 to support existing portfolio companies and new platforms across a broad range of transaction sizes and facility types.
• Raised a Firm record $20.5 billion in new investment capital in 2025, expanding and diversifying Golub Capital’s global investor base.²
• Closed over $9 billion in financing commitments in Europe since 2020.
• Was lead lender on approximately 90% of its direct lending transactions.³
• Delivered strong credit performance, extending an over 20-year track record of annual payment default rates well below the broadly syndicated loan index.⁴

Expanding client service capabilities across investor segments and scaling to meet investor demand in key international markets

• Launched a GP-Led Secondaries strategy, a new initiative focused on investing in continuation vehicles in partnership with leading private equity firms.
• Celebrated five years of operations in London, a key hub for the Firm’s European sponsor finance activity and client service.
• Expanded lending capabilities to include borrowers across technology, healthcare, financial services and business services in the U.K., Germany, France and the Nordics.
• Executed a record $24.4 billion of securitizations and was again the #1 middle market CLO issuer by volume (13 years in a row).⁵
• Now one of the top four U.S. CLO managers by assets under management.⁶

Accelerating impact of philanthropic programs

• Expanded the Golub Capital Nonprofit Board Fellows Network to include 17 of the top 25 U.S. business schools. Now training thousands of MBA candidates and alumni each year to become impactful nonprofit board members.

Earning industry recognition

• Named “Lender of the Year – Americas” by Private Debt Investor.
• Awarded “Best Performance – Private Debt (Mid Cap)” by The Korea Economic Daily.
• Included among Newsweek’s America’s Greatest Midsize Workplaces for 2025.
• Recognized by GrowthCap as one of the year’s Top Private Credit Firms and by ABF Journal on its Value Creators list of top private credit managers.

About Golub Capital

Golub Capital is a market-leading, award-winning direct lender and experienced private credit manager. We specialize in delivering reliable, creative and compelling financing solutions to companies backed by private equity sponsors. Our sponsor finance expertise also forms the foundation of our Broadly Syndicated Loan and Credit Opportunities investment programs. We nurture long-term, win-win partnerships that inspire repeat business from private equity sponsors and investors.

As of January 1, 2026, Golub Capital had over 1,100 employees and over $90 billion of capital under management, a gross measure of invested capital including leverage. The firm has offices in North America, Europe, Asia and the Middle East. For more information, please visit www.golubcapital.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260107420940/en/

Contacts

Media

press@golubcapital.com

VIENNA–(BUSINESS WIRE)– Alpega Group, a leading pan-European provider of an end-to-end transportation and logistics platform, today announced a planned leadership transition. After a successful tenure as Chief Executive Officer, Todd DeLaughter will be retiring, stepping down from his role and transitioning to a Board Advisor role for the company. The Board of Directors has appointed Daniel Cohen as the incoming CEO, effective January 1st, 2026.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108528648/en/

Daniel Cohen, CEO Alpega

Daniel Cohen brings three decades of experience leading B2B SaaS businesses through periods of change, scale, and value realization. Most recently, as CEO of PayU, he led a full financial, operational, and cultural transformation returning the business to sustained profitable growth. He subsequently steered the company through a highly complex, multi-jurisdictional process that culminated in the successful sale to Rapyd. Daniel is recognized for pairing strategic focus with disciplined execution, and for building leadership teams and operating cultures capable of sustained high performance. He joins Alpega Group at a pivotal moment, with the mandate and experience to drive its next phase of profitable growth.

“Alpega brings together strong software assets and a meaningful presence across the transportation ecosystem,” said Daniel Cohen. “As the industry becomes more complex and fragmented, the opportunity is to simplify how transportation is managed and executed through solutions that increase trust and efficiency across the value chain. I’m looking forward to working closely with the team and the Board to build on our strong foundation and continue delivering market-leading products, supported by operational excellence and a culture that drives sustained performance.”

Under DeLaughter’s leadership, Alpega Group has strengthened its position as an industry innovator, expanded its product capabilities, and deepened relationships with shippers, carriers, and logistics partners around the world. His guidance has been instrumental in enhancing Alpega’s suite of software solutions and driving sustainable growth across key markets.

Alpega’s platform has evolved from a number of acquisitions including iNet, Transwide, Teleroute, TenderEasy and Wtransnet. This powerful set of tools includes a comprehensive TMS, transport execution capability, freight procurement and freight exchanges which make up Alpega’s digital transportation platform.

The Board expressed deep appreciation for DeLaughter’s leadership and continuity during the transition.

“On behalf of the entire Board, we thank Todd for his exceptional contributions as CEO,” said Chairman Nikolay Pargov. “We are delighted that he will continue to support the company as a trusted advisor. We have a strong conviction that under Daniel’s guidance, Alpega will enter a new phase of accelerated growth and innovation. The group has strong foundations, refreshed strategy, and a renewed, very talented leadership team. We continue pursuing our goal to deliver industry-leading performance.”

“It has been a privilege to lead Alpega Group through such an important chapter,” said Todd DeLaughter. “I am incredibly proud of what our teams have accomplished and confident that the company is well-positioned for growth above market expectations, Daniel is a strong, visionary leader, and I look forward to supporting him and the company in my advisory role.”

About Alpega Group

Alpega Group is a leading pan-European logistics software company offering end-to-end solutions that empower shippers, carriers, and logistics professionals to streamline and optimize supply chain operations. With decades of industry expertise, Alpega provides powerful Transportation Management Systems (TMS), a well-connected and collaborative Transport Execution Platform, Freight Exchange solutions, and digital tools that drive efficiency, visibility, and collaboration across the transportation ecosystem.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260108528648/en/

Contacts

Media Contact:
Ceren Fuchs

Director of Communications

ceren.fuchs@alpegagroup.com

• FDA IND clearance enabling the worldwide expansion of the INFLAM MOTION Phase 2a trial, involving major U.S. sites
• Advancing the first clinical proof of concept in OA with a first-in-class intra-articular GLP-1 agonist
• A holistic clinical strategy design establishing the foundation for a future accelerated approval pathway

LILLE, France & PARIS–(BUSINESS WIRE)– 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/

4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US).

The U.S. Food and Drug Administration (FDA) approval marks another strategic step in 4MB’s global clinical deployment across Europe, Canada, and now the U.S., reinforcing the company’s role as a front-runner in the race to deliver the first disease-modifying osteoarthritis drug (DMOAD) to patients worldwide. Preclinical studies have shown that 4P004 can modulate multiple biological markers across the whole joint, supporting its potential as a first-in-class DMOAD capable of slowing structural impairment and improving joint function.

“FDA’s clearance of our IND represents a major validation of our program and enables the full execution of our clinical strategy across Europe, Canada, and the United States,” said Luc Boblet, Chief Executive Officer of 4Moving Biotech. “This milestone strengthens our position as one of the most advanced DMOAD developers globally and brings us closer to demonstrating the transformative potential of 4P004 for the millions of patients worldwide who currently have no disease-modifying options.”

The INFLAM MOTION trial is a 3-month, multicenter, randomized, double-blind, placebo-controlled Phase 2a study designed to enroll 129 patients suffering from knee osteoarthritis with synovitis. The trial includes:

• Pain assessment at Week 4 as the primary endpoint
• Pain, function, and contrast-enhanced MRI structural assessment of the synovial membrane at Week 12
• Exploratory surrogate biomarkers predictive of progression

This unique combination of clinical, imaging, and biomarker elements forms the foundation for future interactions with regulatory agencies on accelerated or conditional approval pathways, thereby strategically positioning 4P004 within the highest-priority segment of OA drug development.

“4P004, a GLP-1 receptor agonist administered intra-articularly, allows specific targeting of the diseased joint and joint tissues, aiming to relieve pain while also addressing the underlying disease process, thus offering an exciting novel approach for patients living with painful knee osteoarthritis. As the U.S. Coordinating Investigator, I am pleased to support the INFLAM MOTION study and look forward to evaluating this promising therapeutic approach for patients with knee osteoarthritis.” Thomas J. Schnitzer, MD, PhD, Professor of Medicine, Northwestern University

Professor Francis Berenbaum, MD, PhD, Chief Medical Officer of 4Moving Biotech, concluded: “The regulatory progress across three major regions underscores the scientific robustness of 4P004. INFLAM MOTION is designed to deliver clinically meaningful pain improvement while generating high-resolution structural and biological data to guide the next stage of development. We believe 4P004 has the potential to redefine how osteoarthritis is treated.”

4Moving Biotech will initiate patient enrollment in the United States in Q1 2026, following site activation and investigator onboarding.

About 4Moving Biotech

Founded in 2020 as a spin-off of 4P-Pharma, 4Moving Biotech is a clinical-stage biotechnology company developing disease-modifying drugs for osteoarthritis, one of the world’s most burdensome chronic diseases, affecting more than 600 million people and lacking approved therapies that alter disease course. Headquartered on the Pasteur Institute campus in Lille, 4MB aims to deliver safe, sustainable therapeutic solutions for patients with high unmet medical needs.

Website: www.4movingbiotech.com
LinkedIn: https://fr.linkedin.com/company/4moving–biotech
X : https://x.com/4Moving_Biotech

View source version on businesswire.com: https://www.businesswire.com/news/home/20260107798042/en/

Contacts

Press Contact :

Emmanuel Dadje

Communication Manager

emmanuel.dadje@4P-Pharma.com
Phone : +33 6 30 06 12 13

LEIDEN, Netherlands–(BUSINESS WIRE)– Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan’s 44^th Annual Healthcare Conference on Thursday, January 15.

The company’s presentation will begin at 9:30 am PT/12:30 am ET/6:30 am CET.

The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with neurological involvement including GM1/GM2 gangliosidoses and Niemann-Pick type C disease ((NPC).

Two pivotal Phase 3 studies investigating nizubaglustat in GM1/GM2 gangliosidoses and NPC are currently enrolling, with data expected in 2027. The studies build on positive data from a robust clinical program including the Phase 2 RAINBOW study and the PRONTO natural history study. The Phase 3 studies are financed following the company’s successful completion of €132 million series B round completed in 1H 2025.

About nizubaglustat

Nizubaglustat is a small molecule, orally available and brain penetrant azasugar with a unique dual mode of action, developed as a potential treatment for rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses and Niemann-Pick type C disease (NPC).

Nizubaglustat has received Rare Pediatric Disease Designations (RPDD) for the treatment of GM1 and GM2 gangliosidoses and NPC, Orphan Drug Designations (ODD) for GM1 and GM2 gangliosidosis (Sandhoff and Tay-Sachs Diseases) and NPC, as well as Fast Track Designation and IND clearance for GM1/GM2 gangliosidoses and NPC from the US Food and Drug Administration (FDA). Additionally, nizubaglustat has been awarded Orphan Medicinal Product Designation (OMPD) for the treatment of GM1 and GM2 gangliosidoses by the European Medicines Agency (EMA) and Innovation Passport for the treatment of GM1 and GM2 gangliosidoses from the UK Medicines and Healthcare Products Regulatory Agency (MHRA).

About GM1 and GM2 gangliosidoses

GM1 gangliosidosis and GM2 gangliosidosis (Tay-Sachs and Sandhoff diseases) are lysosomal storage disorders caused by the accumulation of GM1 or GM2 gangliosides respectively, in the central nervous system (CNS). This results in progressive and severe neurological impairment and premature death. These diseases mostly affect infants and children, and no disease-modifying treatments are currently available.

About Niemann-Pick type C disease (NPC)

Niemann-Pick Type C disease is a progressive, life-limiting, neurological, lysosomal storage disorder, caused by mutations in the NPC1 or NPC2 gene and aberrant endosomal-lysosomal trafficking, leading to the accumulation of various lipids, including gangliosides in the CNS. The onset of the disease can happen throughout the lifespan of an affected individual, from prenatal life through adulthood.

About Azafaros

Azafaros is a clinical-stage company founded in 2018 with a deep understanding of rare genetic disease mechanisms using compound discoveries made by scientists at Leiden University and Amsterdam UMC and is led by a team of highly experienced industry experts. Azafaros aims to build a pipeline of disease-modifying therapeutics to offer new treatment options to patients and their families. By applying its knowledge, network and courage, the Azafaros team challenges traditional development pathways to rapidly bring new drugs to the rare disease patients who need them. Azafaros is supported by leading healthcare investors including Forbion, Jeito Capital, Seroba, Pictet Group, BioGeneration Ventures (BGV), BioMedPartners, Asahi Kasei Pharma Ventures, and Schroders Capital.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260107697050/en/

Contacts

For further information:
Azafaros B.V.

Email: info@azafaros.com
www.azafaros.com